Covering the Cost of ALIMTA

PatientOne

The PatientOne program may address financial and coverage concerns for qualified uninsured, insured, and underinsured patients who are prescribed a Lilly Oncology product.

Services available for patients include:

Hotline Information

  • Benefits investigation
  • Reimbursement information
  • Coding and billing information

Uninsured Patient

  • Evaluate other funding options
  • Product assistance for eligible patients

Insured Patient

  • Benefits investigation
  • Prior authorization
  • Denied claims appeals templates, forms, and checklists
  • Appeals status

Underinsured Patient

  • Benefits investigation
  • Information on co-pay assistance programs
  • Transfer to a specific foundation

Talk to your healthcare team's reimbursement specialist to find out more about PatientOne and additional ways to cover the cost of ALIMTA® (pemetrexed for injection) therapy. You can also call the Lilly PatientOne hotline at 1-866-4PatOne (1-866-472-8663).

ALIMTA Indications

ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer medicine (chemotherapy), when surgery is not an option.

ALIMTA can suppress bone marrow function, which may cause low blood cell counts.